Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Adams

Showing results (131-140 of 143) with videos related to

Pageof 15
Sort By:
Journal of the National Cancer Institute|December 5, 2021
Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials MethodologyRichard M Goldberg, Richard Adams, Marc Buyse, et al.
Plos Computational Biology|May 10, 2011
Minimum Information About a Simulation Experiment (MIASE)Dagmar Waltemath, Richard Adams, Daniel A Beard, et al.
Nature Communications|August 8, 2022
Unified classification and risk-stratification in Acute Myeloid LeukemiaYanis Tazi, Juan E Arango-Ossa, Yangyu Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system databaseQian Shi, Aimery de Gramont, Axel Grothey, et al.
BMC Cancer|April 11, 2025
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)Francesca Aroldi, Elena Elez, Thierry André, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2017
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive DatabaseLindsay A Renfro, Richard M Goldberg, Axel Grothey, et al.
Therapeutic Advances in Medical Oncology|July 15, 2021
Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysisJun Yin, Shaheenah Dawood, Romain Cohen, et al.
Epigenetics|September 28, 2013
The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patternsIvana Türbachova, Tim Schwachula, Ines Vasconcelos, et al.
JNCI Cancer Spectrum|May 23, 2022
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical TrialsNadine J McCleary, William S Harmsen, Ellana Haakenstad, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2024
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysisRomain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
Pageof 15

Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Journal of the National Cancer Institute|December 5, 2021
Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials MethodologyRichard M Goldberg, Richard Adams, Marc Buyse, et al.
Plos Computational Biology|May 10, 2011
Minimum Information About a Simulation Experiment (MIASE)Dagmar Waltemath, Richard Adams, Daniel A Beard, et al.
Nature Communications|August 8, 2022
Unified classification and risk-stratification in Acute Myeloid LeukemiaYanis Tazi, Juan E Arango-Ossa, Yangyu Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system databaseQian Shi, Aimery de Gramont, Axel Grothey, et al.
BMC Cancer|April 11, 2025
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)Francesca Aroldi, Elena Elez, Thierry André, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2017
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive DatabaseLindsay A Renfro, Richard M Goldberg, Axel Grothey, et al.
Therapeutic Advances in Medical Oncology|July 15, 2021
Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysisJun Yin, Shaheenah Dawood, Romain Cohen, et al.
Epigenetics|September 28, 2013
The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patternsIvana Türbachova, Tim Schwachula, Ines Vasconcelos, et al.
JNCI Cancer Spectrum|May 23, 2022
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical TrialsNadine J McCleary, William S Harmsen, Ellana Haakenstad, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2024
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysisRomain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
Pageof 15